ARCH funds sell 16K Boundless Bio shares after exercise
Boundless Bio, Inc. received a Form 4 from ARCH-affiliated entities detailing a cashless stock option exercise and same-day sale tied to director Kristina Burow’s compensation.
Rhea-AI Filing Summary
Boundless Bio, Inc. received a Form 4 from ARCH-affiliated entities detailing a cashless stock option exercise and same-day sale tied to director Kristina Burow’s compensation. A stock option for 16,000 shares of common stock was exercised at $1.03 per share and the resulting 16,000 shares were sold in an open-market transaction at $2.49 per share. According to the footnotes, the net proceeds from this exercise and sale were remitted to ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., and ARCH Venture Fund X Overage, L.P., which continue to report substantial indirect holdings of Boundless Bio common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 16,000 shares ($23K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold
16,000 shs ($40K)
Approx. gross sale proceeds
$40K
Approx. exercise cost
$16K
Approx. pre-tax spread
$23K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 16,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 16,000 | $1.03 | $16K |
| Sale | Common Stock | 16,000 | $2.49 | $40K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Indirect, See footnote);
Common Stock — 0 shares (Indirect, See footnote);
Common Stock — 2,694,095 shares (Indirect, See footnotes)
Footnotes (7)
- F1. Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer.
- F2. Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
- F3. Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
- F4. ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
- F5. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
- F6. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
- F7. The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders.
Key Figures
Shares sold: 16,000 shares
Sale price: $2.49 per share
Option exercise size: 16,000 shares
+4 more
7 metrics
Shares sold
16,000 shares
Common stock sold in open-market transaction
Sale price
$2.49 per share
Price for 16,000 Boundless Bio shares sold
Option exercise size
16,000 shares
Stock option exercised into common stock
Option exercise price
$1.03 per share
Exercise price of stock option
ARCH IX holding
1,181,766 shares
Common stock held indirectly by ARCH Venture Fund IX
ARCH IX Overage holding
828,570 shares
Common stock held indirectly by ARCH Venture Fund IX Overage
ARCH X Overage holding
683,759 shares
Common stock held indirectly by ARCH Venture Fund X Overage
Key Terms
cashless stock option exercise, beneficially own, pecuniary interest, indirect, +2 more
6 terms
cashless stock option exercise financial
"Represents a cashless stock option exercise by Kristina Burow."
beneficially own financial
"may be deemed to beneficially own the shares held by ARCH IX"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"each disclaims beneficial ownership except to the extent of any pecuniary interest therein"
indirect financial
"ownership_type: indirect, ownership_code: I"
stock option financial
"The stock option was granted to Kristina Burow in connection with her service"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Boundless Bio (BOLD) report on this Form 4?
The Form 4 reports a cashless stock option exercise for 16,000 Boundless Bio shares at $1.03 per share, followed by an open-market sale of the same 16,000 shares at $2.49 per share, tied to director compensation.
Who is associated with the Boundless Bio (BOLD) Form 4 transactions?
The transactions relate to a stock option granted to director Kristina Burow, with net proceeds remitted to ARCH Venture Fund IX, ARCH Venture Fund IX Overage, and ARCH Venture Fund X Overage, which are the reporting ARCH-affiliated investment funds.
What does a cashless stock option exercise mean in the Boundless Bio (BOLD) filing?
A cashless exercise lets the holder use part of the option’s value to cover the exercise cost. Here, a 16,000-share option at $1.03 was exercised and the resulting 16,000 shares were sold at $2.49, with net proceeds delivered to ARCH funds.
What prices were involved in the Boundless Bio (BOLD) option exercise and sale?
The stock option was exercised at an exercise price of $1.03 per share for 16,000 shares. The resulting 16,000 shares of Boundless Bio common stock were then sold in an open-market transaction at $2.49 per share by the ARCH-affiliated entities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
